All 46 people with HIV who started long-acting lenacapavir and cabotegravir at a University of California, San Francisco, clinic reached or kept viral suppression over a median of 100 weeks.
News|Articles|December 27, 2023
Top 5 HIV Articles in 2023
Author(s)MHE Staff
This year's top HIV articles include one sharing data from a group of researchers from University of Pittsburgh who looked to see if T cell activation is sufficient to drive SIV disease progression.
Advertisement
- T Cell Activation Seen as Insufficient to Drive HIV Infection
Chronic T cell immune activation and inflammation are key features of HIV-1 infection in humans and simian immunodeficiency virus (SIV) infection of rhesus macaques, and a group of researchers from University of Pittsburgh looked to see if T cell activation is sufficient to drive SIV disease progression.Read here - Immune Checkpoint Inhibitors Study for People Living With HIV Shows Promising Results
Researchers and clinicians have been wary of treating people living with HIV with Keytruda, Opdivo and other immune checkpoint inhibitors because removing an inhibitory step in the immune response was seen as risky for people with compromised immune systems.Read here
- HIV Stays Controlled in These Individuals Even After They Stop Treatment. Understanding Why Could Provide Clues to a ‘Functional Cure'
A team of researchers studied 22 HIV 'post-treatment controllers' — people whose HIV infections are kept in check even after stopping antiretroviral therapy.Read here - Advancing Options for Gene Editing for HIV-1
CRISPR gene-editing therapy is predicted to cost about $1 million dollars per person which is considerably more expensive than keeping a patient on ART for the rest of their life.Read here - On Long-Term Treatment, Piggybacking on Hepatitis C Eradication and the ‘Biggest Buzz' in HIV: A Conversation with Angel I. Ribó, PA-C, MPAS
Ribó is the faculty advisor to new POCN Center for HIV Excellence that will provide information and resources to providers who may see relatively few patients with HIV.Read here
Advertisement
Related to this article
Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
Rex Hoffman, M.D., on physician burnout and collaborative leadership | HSES 2026
3
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
4
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
5